Impact of Elosulfase Alfa on Pain in Patients with Morquio A Syndrome over 52 Weeks

Impact of Elosulfase Alfa on Pain in Patients with Morquio A Syndrome over 52 Weeks

Patients with mucopolysaccharidosis (MPS), and Morquio A syndrome (MPS IVA) in particular, often report substantial pain burden. MOR-008 was a randomized, double-blind, pilot study assessing the safety and efficacy, including impact on patient-reported pain, of 52 weeks of treatment with elosulfase...

Full description

Bibliographic Details
Main Authors: Marsha Treadwell, Paul R. Harmatz, Barbara K. Burton, John J. Mitchell, Nicole Muschol, Simon A. Jones, Gregory M. Pastores, Heather A. Lau, Rebecca Sparkes, V. Reid Sutton, Bianca Meesen, Christine A. Haller, Adam J. Shaywitz, Jeffrey I. Gold
Format: Article
Language:English
Published: SciELO 2017-07-01
Series:Journal of Inborn Errors of Metabolism and Screening
Online Access:https://doi.org/10.1177/2326409817718850

Internet

https://doi.org/10.1177/2326409817718850

Similar Items